AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

AUTL · NASDAQ · Biotechnology

Autolus Therapeutics (ADR)

Commercializes AUCATZYL while developing programmed T-cell therapies for cancer and autoimmune diseases.

$2.34

After-hours close+0.01 (+0.43%)

At close$2.33(−1.27%)

Something off on this page? Send us feedback.

Profile

Autolus Therapeutics plcAUTLHealth Care

Sells AUCATZYL, an autologous CAR-T therapy for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. The early commercial business is centered on US delivery, with a UK launch and an EU rollout subject to local access decisions.

Built around autologous CAR-T cell therapy, the business sells AUCATZYL for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia in the United States. Its first US sale marked the shift from a clinical platform to early commercial delivery.

Research continues on next-generation programmed T-cell therapies for cancer and autoimmune diseases, rooted in a University College London spinout founded by Martin Pule. Operations span London and a US office in Maryland.

Market access differs by region: AUCATZYL launched in the UK through NHS commissioning, while an EU launch remains on hold during pricing and market-feasibility evaluation. Regulatory authorization and country-specific access decisions shape expansion.

Company facts

CEOChristian Itin, Ph.D.

ListedJun 22, 2018

ExchangeNASDAQ

HeadquartersLondon, United Kingdom

CountryUnited Kingdom

Employees752

CIK0001730463

ISINUS05280R1005

Key statistics

Market cap$622.8M

EPS (ttm)−$1.06

P/E (ttm)−2.21

ROE-178.6%

P/B8.32

P/S5.31

Dividend yield—

Beta1.97vs XLV 0.93

Year to date +24.6% · Average volume (30d) 2.6M

Analysts

Price target, next 12 months$8.00+241.9%Median of 14 analysts · vs the Aug 28 close

ConsensusBuy11 of 14 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $2.34

High$11.00+370.1%

Median$8.00+241.9%

Low$7.60+224.8%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Prior rating	Rating	Target
Nov 18, 2024	Goldman Sachs	Upgrade	Neutral	Buy	$7.60
Nov 15, 2024	Redburn Atlantic	Upgrade	Neutral	Buy

Earnings

EPS

Estimate−$0.20

ReportedDue Nov 11, 2026

Revenue

Estimate$40.0M

ReportedDue Nov 11, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 11, 2026Q2 FY26	−$0.21	−$0.15	+28.6%	$38.6M	$45.7M	+18.5%	+12.56%
May 14, 2026Q1 FY26	−$0.29	−$0.27	+6.9%	$26.3M	$26.2M	−0.2%	+2.52%
Mar 27, 2026Q4 FY25	−$0.26	−$0.34	−30.8%	$23.9M	$24.3M	+1.6%	+4.96%
Nov 12, 2025Q3 FY25	−$0.23	−$0.30	−30.4%	$24.4M	$21.2M	−13.2%	−5.88%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$9.0M	$20.9M	$21.2M	$24.3M	$26.2M	$45.7M
Gross profit	−$9.0M	−$3.5M	−$7.4M	−$1.0M	$1.7M	$25.2M
Operating income	−$65.2M	−$61.2M	−$71.6M	−$72.4M	−$59.5M	−$43.8M
Net income	−$70.2M	−$47.9M	−$79.1M	−$90.2M	−$71.6M	−$39.1M
Diluted EPS	−$0.26	−$0.18	−$0.30	−$0.34	−$0.27	−$0.15
Gross margin	-99.9%	-16.8%	-35.1%	-4.3%	6.3%	55.2%
Operating margin	-726.3%	-292.6%	-337.9%	-298.3%	-227.0%	-95.9%

Fiscal years (4-quarter sums)FY21 $2.3M · FY22 $6.2M · FY23 $1.7M · FY24 $10.1M · FY25 $75.4M

Revenue by product · Q2 FY26

Product$45.7M · 100%

License$17.0K · 0%

Revenue by geography · FY25

United States$1.0M · 95%

Europe$50.0K · 5%

Balance sheet, Jun 30, 2026Cash & short-term investments $201.6M · Total debt $83.5M · Total assets $493.2M · Shareholders' equity $74.8M

Dividends

No dividends on record.

Ownership

Institutions 50.51%134.44M sharesInsiders 0.53%1.41M sharesOther 48.96%130.29M shares

Shares outstanding 266.14M · Float 240.52M · 90.4% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
MAK Capital Fund LP	33.62M	12.60%	13G	May 15, 2026
Wellington Investment Advisors Holdings LLP	24.22M	9.11%	13G	Nov 8, 2024
Blackstone Inc.	20.49M	7.70%	13F	May 15, 2026
Syncona Portfolio Ltd	16.64M	6.25%	13F	May 14, 2026
Armistice Capital, LLC	15.80M	5.94%	13G	May 15, 2026

Insider tradesForm 4

No open-market trades in the last 12 months.